language

Looking for reliable pharma & medical sourcing?

REQUEST QUOTE

Rely on 70+ years of group manufacturing strength, international certified products and full-chain after-service. Submit inquiry now.

BLOG & EVENT

Blog & Event

Company News

Exhibition

Home

Jun 22,2026

Two New Drug Varieties (Three Specifications) of SSY Group Obtain Approval

On June 22, two new pharmaceutical varieties with three specifications independently developed by SSY Group obtained production registration approvals issued by the National Medical Products Administration (NMPA), and were deemed to have passed the Consistency Evaluation of Quality and Efficacy of Generic Drugs.

Jun 15,2026

Cefpodoxime Proxetil Dry Suspension (50mg) of SSY Group Granted Approval

On June 15, the Class 3 chemical drug Cefpodoxime Proxetil Dry Suspension (50mg) independently developed by SSY Group obtained the production registration approval issued by the National Medical Products Administration (NMPA)

Jun 08,2026

SSY Group Obtains Registration Approvals for Ceftizoxime Sodium for Injection (1.0g & 0.5g)

On June 8, SSY Group obtained registration approval documents for two specifications of Ceftizoxime Sodium for Injection (1.0g and 0.5g). Since the start of this year, the Group has secured 44 new product approvals, including 33 for finished preparations and 11 for APIs.

Jun 04,2026

Shijiazhuang No.4 Pharmaceutical Boosts Development of Modified Innovative Drugs

Per the agreement, the two parties will jointly develop a Class 2.2 antispasmodic medicine for children and a Class 2.3 therapeutic drug for chronic obstructive pulmonary disease (COPD). Both are modified new chemical drugs designed to address unmet clinical medical demands.

Jun 05,2026

SSY Golden Gate Shines at Overseas Pharmaceutical Raw Material Exhibition

We secured multiple prospective cooperation deals after exhibiting core API and finished drug lines.The exhibition effectively expanded our global sales channels and built new long-term partnership intentions.